• Dragana Lazarević Clinic of Pediatrics, Rheumatologist, University Clinical Center Niš, Faculty of Medicine
  • Maja Zečević University of Niš, Faculty of Medicine




juvenile idiopathic arthritis, oligoarticular juvenile idiopathic arthritis, treatment


The oligoarticular subtype of juvenile idiopathic arthritis (JIA) clinically defines the presence of arthritis in fewer than five joints in the first six months of the disease. If arthritis affects less than five joints thought the disease, then we are talking about persistent oligoarthritis. If arthritis affects 5 or more joints after 6 months from the disease onset, we are talking about an extended form of oligoarthritis. In recent decades, JIA etiopathogenesis novelties and genetic engineering improvement enabled new therapeutic strategies which have improved the disease course and clinical outcome. The modern concept of treatment ensured better quality of life, reduced disease activity and subjective complaints, enabled normal children growth, preserved joint functionality and prevented onset of disability and work incapacity. The modern concept of JIA treatment tends to individualize treatment approach. Compared to other subtypes of JIA, the oligoarticular form has the best prognosis, especially if we are talking about the persistent subtype of oligoarthritis.


Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2.

Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995;22(8):1566-9.

Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009 Oct;23(5):655-64.

Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021 Aug 23;19(1):135.

Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011 Jun 18;377(9783):2138-49.

Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am. 2018 Aug;65(4):657-674.

Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology 2004;111(12):2299-306.

Bou R, Iglesias E, Anton J. Treatment of uveitis associated with juvenile idiopathic arthritis. Curr Rheumatol Rep 2014;16(8):437. doi:10.1007/s11926-014-0437-4.

Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007;56(2):647-57.

Bou R, Adan A, Borras F, Bravo B, Calvo I, De Inocencio J, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 2015;35(5):777-85.

Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007;46(6):1015-9.

Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140(3):509-16.

Heiligenhaus A, Minden K, Foll D, Pleyer U. Uveitis in juvenile idiopathic arthritis. Arztebl Int 2015;112(6):92-100.

Collado P, Gamir ML, Lopez-Robledillo JC, Merino R, Modesto C, Monteagudo I. Detection of synovitis by ultrasonography in clinically inactive juvenile idiopathic arthritis on and off medication. Clin Exp Rheumatol 2014;32(4):597-603.

Colebatch-Bourn AN, Edwards CJ, Collado P, D'Agostino MA, Hemke R, Jousse-Joulin S, et al. EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Ann Rheum Dis 2015;74(11):1946-57.

Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63(4):465-82.

Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-734.

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68(4):519-25.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68(5):635-41.

Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 2014;66(9):2580-9.

Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74(10):1854-60.

Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, et al. Current news from the BIKER register. Z Rheumatol 2014;73(10):897-906.






Review Articles